Shares of Fortress Biotech, Inc. (FBIO) surged Monday after the company announced a $205 million asset sale tied to a Rare Pediatric Disease Priority Review Voucher.
The stock is currently trading at $3.9698, up $0.6098 or 18.15%, on the Nasdaq. The stock opened at $3.7900 after closing Friday at $3.3600. The stock has traded between $1.3300 and $4.5300 in the past 52-week period. Trading volume soared far above average.
Fortress said its subsidiary Cyprium Therapeutics entered an agreement to sell its Rare Pediatric Disease Priority Review Voucher for $205 million in gross proceeds. The voucher was granted following the FDA approval of ZYCUBO for Menkes disease in January 2026.
Cyprium remains eligible for royalties on ZYCUBO sales and up to $129 million in milestone payments.
For comments and feedback contact: editorial@rttnews.com
Business News
June 12, 2026 17:14 ET Major central bank action was the focus this week in economic news. The European Central Bank became the first major central bank to move in response to the rising inflationary pressures in the backdrop of the conflict in the Middle East. In North America, the U.S. inflation and trade data as well as Canada’s central bank decision gained attention. The Chinese trade data was the main news in Asia.